Begin typing your search above and press return to search.

BHU wants clinical trial of drug to cure COVID-19

By The Assam Tribune

VARANASI, April 24 - Banaras Hindu University (BHU) wants to carry out a clinical trial of immunity-boosting ayurvedic drug 'Fifatrol' to check its efficacy in tackling the deadly COVID-19.

However, the proposal is yet to be approved, official sources said.

According to BHU professor and principal investigator for the proposed project, Dr KN Dwivedi, the plan has been sent to a task force formed by the government for scientific validation of Ayurveda and traditional medicinal formulas through research institutions in tackling COVID-19.

The inter-disciplinary AYUSH Research and Development Task Force has members from the Department of Biotechnology (DBT), Council of Scientific and Industrial Research (CSIR) and also AYUSH practitioners and others.

The scientists are trying to identify potential preventive therapy and therapeutic approaches from AYUSH systems in different stages of COVID-19 treatment. - IANS

Next Story
Similar Posts
BHU wants clinical trial of drug to cure COVID-19

VARANASI, April 24 - Banaras Hindu University (BHU) wants to carry out a clinical trial of immunity-boosting ayurvedic drug 'Fifatrol' to check its efficacy in tackling the deadly COVID-19.

However, the proposal is yet to be approved, official sources said.

According to BHU professor and principal investigator for the proposed project, Dr KN Dwivedi, the plan has been sent to a task force formed by the government for scientific validation of Ayurveda and traditional medicinal formulas through research institutions in tackling COVID-19.

The inter-disciplinary AYUSH Research and Development Task Force has members from the Department of Biotechnology (DBT), Council of Scientific and Industrial Research (CSIR) and also AYUSH practitioners and others.

The scientists are trying to identify potential preventive therapy and therapeutic approaches from AYUSH systems in different stages of COVID-19 treatment. - IANS